{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:49:56Z","timestamp":1792594196654,"version":"4.5.0"},"reference-count":240,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.berh.2018.09.001","type":"journal-article","created":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T12:59:50Z","timestamp":1541163590000},"page":"271-294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Update on the epidemiology, risk factors, and outcomes of systemic vasculitides"],"prefix":"10.1016","volume":"32","author":[{"given":"Alvise","family":"Berti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Dejaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2018.09.001_bib1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/art.1780370206","article-title":"Nomenclature of systemic vasculitides. Proposal of an international consensus conference","volume":"37","author":"Jennette","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib2","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nrrheum.2016.123","article-title":"Anca-associated vasculitis \u2013 clinical utility of using anca specificity to classify patients","volume":"12","author":"Cornec","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised international chapel hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib4","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/art.24459","article-title":"Epidemiology of giant cell arteritis and polymyalgia rheumatica","volume":"61","author":"Gonzalez-Gay","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib5","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1445-5994.1984.tb03769.x","article-title":"Vasculitis and glomerulonephritis: a subgroup with an antineutrophil cytoplasmic antibody","volume":"14","author":"Hall","year":"1984","journal-title":"Aust N Z J Med"},{"key":"10.1016\/j.berh.2018.09.001_bib6","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1016\/j.lpm.2017.05.034","article-title":"Epidemiology of takayasu arteritis","volume":"46","author":"Onen","year":"2017","journal-title":"Presse Med"},{"key":"10.1016\/j.berh.2018.09.001_bib7","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/acr.22931","article-title":"Prevalence, incidence, and disease characteristics of takayasu arteritis by ethnic background: data from a large, population-based cohort resident in southern Norway","volume":"69","author":"Gudbrandsson","year":"2017","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2018.09.001_bib8","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1093\/rheumatology\/kex300","article-title":"Assessment of the frequency of cardiovascular risk factors in patients with takayasu's arteritis","volume":"56","author":"Alibaz-Oner","year":"2017","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.berh.2018.09.001_bib9","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1161\/CIRCULATIONAHA.116.027094","article-title":"Long-term outcomes and prognostic factors of complications in takayasu arteritis: a multicenter study of 318 patients","volume":"136","author":"Comarmond","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.berh.2018.09.001_bib10","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/art.40313","article-title":"The epidemiology of anca associated vasculitis in olmsted county, Minnesota (USA): a 20 year population-based study","volume":"69","author":"Berti","year":"2017","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.berh.2018.09.001_bib11","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/rheumatology\/kep304","article-title":"Incidence and survival rates in wegener's granulomatosis, microscopic polyangiitis, churg-strauss syndrome and polyarteritis nodosa","volume":"48","author":"Mohammad","year":"2009","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.berh.2018.09.001_bib12","first-page":"589","article-title":"The incidence, prevalence and mortality of granulomatosis with polyangiitis in the UK clinical practice research datalink","volume":"56","author":"Pearce","year":"2016","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.berh.2018.09.001_bib13","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.autrev.2018.01.022","article-title":"Mortality in systemic necrotizing vasculitides: a retrospective analysis of the French vasculitis study group registry","volume":"17","author":"Jardel","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2018.09.001_bib14","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1136\/annrheumdis-2016-210942","article-title":"Mortality in anca-associated vasculitis: ameta-analysis of observational studies","volume":"76","author":"Tan","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/rheumatology\/keu129.008","article-title":"The epidemiology of vasculitis in the UK","volume":"53","author":"Watts","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2018.09.001_bib16","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/rheumatology\/kex158","article-title":"Incidence of iga vasculitis in children estimated by four-source capture-recapture analysis: a population-based study","volume":"56","author":"Piram","year":"2017","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.berh.2018.09.001_bib17","first-page":"11","article-title":"Epidemiological study of primary systemic vasculitides among adults in southern Spain and review of the main epidemiological studies","volume":"33","author":"Romero-Gomez","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib18","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1056\/NEJM199711203372106","article-title":"Small-vessel vasculitis","volume":"337","author":"Jennette","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2018.09.001_bib19","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"Eular\/era-edta recommendations for the management of anca-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib20","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.2215\/CJN.02500317","article-title":"Anca glomerulonephritis and vasculitis","volume":"12","author":"Jennette","year":"2017","journal-title":"Clin J Am Soc Nephrol : CJASN"},{"key":"10.1016\/j.berh.2018.09.001_bib21","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrrheum.2010.158","article-title":"Anca-associated vasculitides--advances in pathogenesis and treatment","volume":"6","author":"Chen","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib22","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1681\/ASN.2014090903","article-title":"Proteinase 3-anca vasculitis versus myeloperoxidase-anca vasculitis","volume":"26","author":"Hilhorst","year":"2015","journal-title":"J\u00a0Am Soc Nephrol : JASN"},{"key":"10.1016\/j.berh.2018.09.001_bib23","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1002\/art.34562","article-title":"Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis","volume":"64","author":"Lionaki","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib24","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1093\/ndt\/gfu084","article-title":"Anca serotype and histopathological classification for the prediction of renal outcome in anca-associated glomerulonephritis","volume":"29","author":"Quintana","year":"2014","journal-title":"Nephrol Dial Transplant : Off Publ Eur Dial Transpl Assoc \u2013 Eur Ren Assoc"},{"key":"10.1016\/j.berh.2018.09.001_bib25","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-143-9-200511010-00005","article-title":"Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis","volume":"143","author":"Hogan","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2018.09.001_bib26","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJMoa1108735","article-title":"Genetically distinct subsets within anca-associated vasculitis","volume":"367","author":"Lyons","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2018.09.001_bib27","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/art.40471","article-title":"Circulating cytokine profiles and antineutrophil cytoplasmic antibody specificity in patients with antineutrophil cytoplasmic antibody-associated vasculitis","volume":"70","author":"Berti","year":"2018","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.berh.2018.09.001_bib28","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/annrheumdis-2015-208073","article-title":"Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (anca)-associated vasculitis based on anca type","volume":"75","author":"Unizony","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib29","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/art.39637","article-title":"Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3","volume":"68","author":"Fussner","year":"2016","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.berh.2018.09.001_bib30","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3899\/jrheum.131038","article-title":"A\u00a0population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (anca)-associated nephritis versus myeloperoxidase anca-associated nephritis","volume":"41","author":"Mohammad","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib31","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1002\/art.39812","article-title":"Myeloperoxidase-antineutrophil cytoplasmic antibody (anca)-positive and anca-negative patients with granulomatosis with polyangiitis (wegener's): distinct patient subsets","volume":"68","author":"Miloslavsky","year":"2016","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.berh.2018.09.001_bib32","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1002\/art.39786","volume":"68","author":"Schirmer","year":"2016","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.berh.2018.09.001_bib33","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.1780330807","article-title":"The american college of rheumatology 1990 criteria for the classification of wegener's granulomatosis","volume":"33","author":"Leavitt","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib34","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/art.1780330806","article-title":"The american college of rheumatology 1990 criteria for the classification of churg-strauss syndrome (allergic granulomatosis and angiitis)","volume":"33","author":"Masi","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib35","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/ard.2006.054593","article-title":"Development and validation of a consensus methodology for the classification of the anca-associated vasculitides and polyarteritis nodosa for epidemiological studies","volume":"66","author":"Watts","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib36","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s10157-013-0854-0","article-title":"Acr\/eular-endorsed study to develop diagnostic and classification criteria for vasculitis (dcvas)","volume":"17","author":"Craven","year":"2013","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.berh.2018.09.001_bib37","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for anca-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2018.09.001_bib38","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/art.39450","article-title":"Long-term outcomes among participants in the wegent trial of remission-maintenance therapy for granulomatosis with polyangiitis (wegener's) or microscopic polyangiitis","volume":"68","author":"Puechal","year":"2016","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"Suppl 1","key":"10.1016\/j.berh.2018.09.001_bib39","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/ndt\/gfv045","article-title":"Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function","volume":"30","author":"McGregor","year":"2015","journal-title":"Nephrol Dial Transplant : Off Publ Eur Dial Transpl Assoc \u2013 Eur Ren Assoc"},{"key":"10.1016\/j.berh.2018.09.001_bib40","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/rheumatology\/keu366","article-title":"Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European vasculitis study group trials","volume":"54","author":"Robson","year":"2015","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.berh.2018.09.001_bib41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/annrheumdis-2013-203927","article-title":"Damage in the anca-associated vasculitides: long-term data from the european vasculitis study group (euvas) therapeutic trials","volume":"74","author":"Robson","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib42","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of c5a receptor inhibitor avacopan in anca-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J\u00a0Am Soc Nephrol : JASN"},{"key":"10.1016\/j.berh.2018.09.001_bib43","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s40674-017-0073-z","article-title":"Current and future treatment options for eosinophilic granulomatosis with polyangiitis","volume":"3","author":"Berti","year":"2017","journal-title":"Curr Treat Options Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib44","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2018.09.001_bib45","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2014-206095","article-title":"Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (churg-strauss)","volume":"75","author":"Mohammad","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib46","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/art.40205","article-title":"Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis, microscopic polyangiitis or polyarteritis nodosa without poor prognosis factors a randomized-controlled trial","volume":"69","author":"Puechal","year":"2017","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"Suppl. 1","key":"10.1016\/j.berh.2018.09.001_bib47","doi-asserted-by":"crossref","first-page":"i14","DOI":"10.1093\/ndt\/gfv022","article-title":"Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (anca)-associated vasculitis","volume":"30","author":"Watts","year":"2015","journal-title":"Nephrol Dial Transplant : Off Publ Eur Dial Transpl Assoc \u2013 Eur Ren Assoc"},{"key":"10.1016\/j.berh.2018.09.001_bib48","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1093\/rheumatology\/kex293","article-title":"Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"56","author":"Pearce","year":"2017","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.berh.2018.09.001_bib49","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/rheumatology\/kew232","article-title":"Incidence of anca-associated vasculitis in a UK mixed ethnicity population","volume":"55","author":"Pearce","year":"2016","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.berh.2018.09.001_bib50","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.mayocp.2011.11.009","article-title":"Generalizability of epidemiological findings and public health decisions: an illustration from the rochester epidemiology project","volume":"87","author":"St Sauver","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.berh.2018.09.001_bib51","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1093\/ije\/dys195","article-title":"Data resource profile: the rochester epidemiology project (rep) medical records-linkage system","volume":"41","author":"St Sauver","year":"2012","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.berh.2018.09.001_bib52","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/aje\/kwq482","article-title":"Use of a medical records linkage system to enumerate a dynamic population over time: the rochester epidemiology project","volume":"173","author":"St Sauver","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.berh.2018.09.001_bib53","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM198806233182504","article-title":"Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis","volume":"318","author":"Falk","year":"1988","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2018.09.001_bib54","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.semarthrit.2014.05.005","article-title":"Epidemiology of granulomatosis with polyangiitis (wegener's granulomatosis) in northern Italy: a 15-year population-based study","volume":"44","author":"Catanoso","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib55","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/ard.60.12.1156a","article-title":"Epidemiology of vasculitis in europe","volume":"60","author":"Watts","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib56","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/rheumatology\/ker205","article-title":"Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K","volume":"50","author":"Fujimoto","year":"2011","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.berh.2018.09.001_bib57","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.2215\/CJN.01020113","article-title":"Renal survival in proteinase 3 and myeloperoxidase anca-associated systemic vasculitis","volume":"8","author":"de Joode","year":"2013","journal-title":"Clin J Am Soc Nephrol : CJASN"},{"key":"10.1016\/j.berh.2018.09.001_bib58","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s10067-016-3232-y","article-title":"The epidemiology of antineutrophil cytoplasmic antibody-associated vasculitis in northwestern Turkey","volume":"35","author":"Pamuk","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib59","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/rheumatology\/kem107","article-title":"Prevalence of wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and churg-strauss syndrome within a defined population in southern Sweden","volume":"46","author":"Mohammad","year":"2007","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.berh.2018.09.001_bib60","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/art.20077","article-title":"Prevalences of polyarteritis nodosa, microscopic polyangiitis, wegener's granulomatosis, and churg-strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate","volume":"51","author":"Mahr","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib61","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/1529-0131(200002)43:2<414::AID-ANR23>3.0.CO;2-0","article-title":"Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom","volume":"43","author":"Watts","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib62","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1002\/1529-0131(200011)43:11<2481::AID-ANR15>3.0.CO;2-6","article-title":"Epidemiology of wegener's granulomatosis in northern Norway","volume":"43","author":"Koldingsnes","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib63","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00005792-199909000-00002","article-title":"Systemic vasculitis in adults in northwestern Spain, 1988\u20131997. Clinical and epidemiologic aspects","volume":"78","author":"Gonzalez-Gay","year":"1999","journal-title":"Medicine"},{"key":"10.1016\/j.berh.2018.09.001_bib64","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/rheumatology\/41.5.540","article-title":"No difference in the incidences of vasculitides between north and south Germany: first results of the German vasculitis register","volume":"41","author":"Reinhold-Keller","year":"2002","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.berh.2018.09.001_bib65","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/ard.60.2.170","article-title":"Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of europe","volume":"60","author":"Watts","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib66","first-page":"284","article-title":"Systemic vasculitis in the 1980s\u2013is there an increasing incidence of wegener's granulomatosis and microscopic polyarteritis?","volume":"24","author":"Andrews","year":"1990","journal-title":"J\u00a0Roy Coll Phys Lond"},{"key":"10.1016\/j.berh.2018.09.001_bib67","first-page":"2060","article-title":"Increasing incidence of wegener's granulomatosis in Sweden, 1975-2001","volume":"33","author":"Knight","year":"2006","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib68","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/rheumatology\/ker454","article-title":"The contrasting epidemiology of granulomatosis with polyangiitis (wegener's) and microscopic polyangiitis","volume":"51","author":"Watts","year":"2012","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.berh.2018.09.001_bib69","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1681\/ASN.2010101058","article-title":"Drb1*15 allele is a risk factor for pr3-anca disease in african americans","volume":"22","author":"Cao","year":"2011","journal-title":"J\u00a0Am Soc Nephrol : JASN"},{"key":"10.1016\/j.berh.2018.09.001_bib70","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1136\/annrheumdis-2015-207601","article-title":"Genetic variants in anca-associated vasculitis: a meta-analysis","volume":"75","author":"Rahmattulla","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib71","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/art.40034","article-title":"Identification of functional and expression polymorphisms associated with risk for anti-neutrophil cytoplasmic autoantibody-associated vasculitis","volume":"69","author":"Merkel","year":"2016","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.berh.2018.09.001_bib72","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1093\/rheumatology\/ket226","article-title":"Does geographic location affect incidence of anca-associated renal vasculitis in northern saskatchewan, Canada?","volume":"52","author":"Anderson","year":"2013","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.berh.2018.09.001_bib73","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/art.1780390112","article-title":"The epidemiology of wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources","volume":"39","author":"Cotch","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"e8","key":"10.1016\/j.berh.2018.09.001_bib74","first-page":"55","article-title":"Wegener's granulomatosis and environmental factors in western Montana","volume":"1","author":"Zeft","year":"2010","journal-title":"Rheumatol Rep"},{"key":"10.1016\/j.berh.2018.09.001_bib75","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1445-5994.2008.01672.x","article-title":"Epidemiology of primary systemic vasculitis in the australian capital territory and south-eastern new south wales","volume":"38","author":"Ormerod","year":"2008","journal-title":"Intern Med J"},{"key":"10.1016\/j.berh.2018.09.001_bib76","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3109\/14397595.2013.857582","article-title":"A\u00a0nationwide survey on the epidemiology and clinical features of eosinophilic granulomatosis with polyangiitis (churg-strauss) in Japan","volume":"24","author":"Sada","year":"2014","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib77","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/rheumatology\/ket440","article-title":"Reinhold-Keller E. Doubled prevalence rates of anca-associated vasculitides and giant cell arteritis between 1994 and 2006 in northern Germany","volume":"53","author":"Herlyn","year":"2014","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.berh.2018.09.001_bib78","doi-asserted-by":"crossref","first-page":"A638","DOI":"10.1136\/annrheumdis-2013-eular.1892","article-title":"Sat 0166 the incidences of anti-neutrophil cytoplasmic antibody-associated vasculitis in northeastern part of Turkey","volume":"72","author":"Pamuk","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib79","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/art.37721","article-title":"Eosinophilic granulomatosis with polyangiitis (churg-strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French vasculitis study group cohort","volume":"65","author":"Comarmond","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib80","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13023-016-0523-y","article-title":"Childhood-onset granulomatosis with polyangiitis and microscopic polyangiitis: systematic review and meta-analysis","volume":"11","author":"Iudici","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib81","first-page":"1","article-title":"Epidemiology of primary systemic vasculitis in children: a population-based study from southern Sweden","author":"Mossberg","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib82","first-page":"S52","article-title":"Incidence of granulomatosis with polyangiitis (wegener's) in Greenland and the Faroe Islands: epidemiology of an anca-associated vasculitic syndrome in two ethnically distinct populations in the north atlantic area","volume":"31","author":"Faurschou","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib83","first-page":"S81","article-title":"Incidence of wegener's granulomatosis in Finland 1981\u20132000","volume":"26","author":"Takala","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib84","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/art.24544","article-title":"Prevalence and incidence of wegener's granulomatosis in the UK general practice research database","volume":"61","author":"Watts","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib85","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00296-009-1275-y","article-title":"Churg-strauss syndrome: retrospective study in burgundian population in France in past 10 years","volume":"31","author":"Vinit","year":"2011","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.berh.2018.09.001_bib86","first-page":"409","article-title":"The epidemiology of primary systemic vasculitides involving small vessels in crete (southern Greece): a comparison of older versus younger adult patients","volume":"27","author":"Panagiotakis","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib87","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jmii.2013.12.006","article-title":"Antineutrophil cytoplasmic antibody-associated vasculitis in taiwan: a hospital-based study with reference to the population-based national health insurance database","volume":"48","author":"Wu","year":"2015","journal-title":"J\u00a0Microbiol Immunol Infect = Wei mian yu gan ran za zhi"},{"key":"10.1016\/j.berh.2018.09.001_bib88","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1445-5994.2008.01694.x","article-title":"Wegener's granulomatosis: epidemiological and clinical features in a south australian study","volume":"38","author":"Hissaria","year":"2008","journal-title":"Intern Med J"},{"key":"10.1016\/j.berh.2018.09.001_bib89","first-page":"1615","article-title":"Seasonal variations in onset of wegener's granulomatosis: increased in summer?","volume":"33","author":"Mahr","year":"2006","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib90","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/art.24790","article-title":"Antineutrophil cytoplasmic antibody-associated vasculitides: could geographic patterns be explained by ambient ultraviolet radiation?","volume":"61","author":"Gatenby","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib91","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/BOR.0000000000000014","article-title":"Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (anca) vasculitis","volume":"26","author":"Pendergraft","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib92","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/ckj\/sfx127","article-title":"Seasonal variations in the onset of positive and negative renal anca-associated vasculitis in Spain","volume":"11","author":"Draibe","year":"2018","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.berh.2018.09.001_bib93","doi-asserted-by":"crossref","first-page":"8188","DOI":"10.1038\/srep08188","article-title":"Low anti-staphylococcal igg responses in granulomatosis with polyangiitis patients despite long-term staphylococcus aureus exposure","volume":"5","author":"Glasner","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.berh.2018.09.001_bib94","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/rheumatology\/kex001","article-title":"Chronic nasal staphylococcus aureus carriage identifies a subset of newly diagnosed granulomatosis with polyangiitis patients with high relapse rate","volume":"56","author":"Salmela","year":"2017","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.berh.2018.09.001_bib95","doi-asserted-by":"crossref","first-page":"12211","DOI":"10.1038\/s41598-017-12450-z","article-title":"Genetic loci of staphylococcus aureus associated with anti-neutrophil cytoplasmic autoantibody (anca)-associated vasculitides","volume":"7","author":"Glasner","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.berh.2018.09.001_bib96","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/nm.1874","article-title":"Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis","volume":"14","author":"Kain","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.berh.2018.09.001_bib97","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/rheumatology\/keq375","article-title":"Bacterial DNA motifs trigger anca production in anca-associated vasculitis in remission","volume":"50","author":"Tadema","year":"2011","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.berh.2018.09.001_bib98","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/rheumatology\/kev293","article-title":"Toll-like receptor 9 activation enhances b cell activating factor and interleukin-21 induced anti-proteinase 3 autoantibody production in\u00a0vitro","volume":"55","author":"Lepse","year":"2016","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.berh.2018.09.001_bib99","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1681\/ASN.2011030273","article-title":"Anti\u2013lamp-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis","volume":"23","author":"Roth","year":"2012","journal-title":"J\u00a0Am Soc Nephrol : JASN"},{"key":"10.1016\/j.berh.2018.09.001_bib100","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.autrev.2013.06.016","article-title":"The association between silica exposure and development of anca-associated vasculitis: systematic review and meta-analysis","volume":"12","author":"Gomez-Puerta","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2018.09.001_bib101","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2215\/CJN.03501006","article-title":"Association of silica exposure with anti-neutrophil cytoplasmic autoantibody small-vessel vasculitis: a population-based, case-control study","volume":"2","author":"Hogan","year":"2007","journal-title":"Clin J Am Soc Nephrol : CJASN"},{"key":"10.1016\/j.berh.2018.09.001_bib102","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.autrev.2012.08.009","article-title":"Cocaine-induced midline destructive lesions - an autoimmune disease?","volume":"12","author":"Trimarchi","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2018.09.001_bib103","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1089\/thy.2017.0468","article-title":"Clinical characteristics and outcomes of propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis in patients with graves' disease: a median 38-month retrospective cohort study from a single institution in China","volume":"27","author":"Yang","year":"2017","journal-title":"Thyroid : Off J Am Thyroid Assoc"},{"key":"10.1016\/j.berh.2018.09.001_bib104","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-98-1-76","article-title":"Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years","volume":"98","author":"Fauci","year":"1983","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2018.09.001_bib105","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A\u00a0randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2018.09.001_bib106","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for anca-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2018.09.001_bib107","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1136\/ard.2008.094714","article-title":"Antimyeloperoxidase antibodies are a useful marker of disease activity in antineutrophil cytoplasmic antibody-associated vasculitides","volume":"68","author":"Terrier","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib108","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1681\/ASN.2010050477","article-title":"Histopathologic classification of anca-associated glomerulonephritis","volume":"21","author":"Berden","year":"2010","journal-title":"J\u00a0Am Soc Nephrol : JASN"},{"key":"10.1016\/j.berh.2018.09.001_bib109","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2215\/CJN.08290813","article-title":"Predictors of treatment outcomes in anca-associated vasculitis with severe kidney failure","volume":"9","author":"Lee","year":"2014","journal-title":"Clin J Am Soc Nephrol : CJASN"},{"key":"10.1016\/j.berh.2018.09.001_bib110","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.1016\/j.lpm.2015.04.008","article-title":"Update on the treatment of anca associated vasculitis","volume":"44","author":"Smith","year":"2015","journal-title":"Presse Med"},{"key":"10.1016\/j.berh.2018.09.001_bib111","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.mayocp.2018.02.010","article-title":"Risk of cardiovascular disease and venous thromboembolism among patients with incident anca-associated vasculitis: a 20-year population-based cohort study","volume":"93","author":"Berti","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.berh.2018.09.001_bib112","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/acr.22686","article-title":"Long-term followup of a multicenter cohort of 101 patients with eosinophilic granulomatosis with polyangiitis (churg-strauss)","volume":"68","author":"Durel","year":"2016","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2018.09.001_bib113","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2012-201531","article-title":"A\u00a0vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (churg-strauss, egpa): monocentric experiences in 150 patients","volume":"72","author":"Moosig","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib114","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in anca-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib115","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/annrheumdis-2012-201750","article-title":"Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis","volume":"72","author":"Mahr","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib116","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1002\/art.39762","article-title":"Risk of myocardial infarction and stroke in patients with granulomatosis with polyangiitis (wegener's): a population-based study","volume":"68","author":"Avina-Zubieta","year":"2016","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.berh.2018.09.001_bib117","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/acr.20433","article-title":"A\u00a0model to predict cardiovascular events in patients with newly diagnosed wegener's granulomatosis and microscopic polyangiitis","volume":"63","author":"Suppiah","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2018.09.001_bib118","doi-asserted-by":"crossref","first-page":"6013038","DOI":"10.1155\/2017\/6013038","article-title":"Cancer in anca-associated glomerulonephritis: a registry-based cohort study","volume":"2017","author":"Sriskandarajah","year":"2017","journal-title":"Int J Nephrol"},{"key":"10.1016\/j.berh.2018.09.001_bib119","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.3899\/jrheum.160909","article-title":"Severe infection in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"44","author":"Mohammad","year":"2017","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib120","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1002\/art.39317","article-title":"Incidence of malignancies in patients with antineutrophil cytoplasmic antibody\u2013associated vasculitis diagnosed between 1991 and 2013","volume":"67","author":"Chinar","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib121","article-title":"All-cause and cause-specific mortality in granulomatosis with polyangiitis: a population-based study","author":"Tan","year":"2018","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2018.09.001_bib122","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3899\/jrheum.110276","article-title":"The omeract core set of outcome measures for use in clinical trials of anca-associated vasculitis","volume":"38","author":"Merkel","year":"2011","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib123","first-page":"671","article-title":"Birmingham vasculitis activity score (bvas) in systemic necrotizing vasculitis","volume":"87","author":"Luqmani","year":"1994","journal-title":"QJM : Mon J Assoc Phys"},{"key":"10.1016\/j.berh.2018.09.001_bib124","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5","article-title":"A\u00a0disease-specific activity index for wegener's granulomatosis: modification of the birmingham vasculitis activity score. International network for the study of the systemic vasculitides (inssys)","volume":"44","author":"Stone","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib125","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the birmingham vasculitis activity score (version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib126","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/art.1780400222","article-title":"Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides","volume":"40","author":"Exley","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib127","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00005650-199303000-00006","article-title":"The mos 36-item short-form health survey (sf-36): ii. Psychometric and clinical tests of validity in measuring physical and mental health constructs","volume":"31","author":"McHorney","year":"1993","journal-title":"Med Care"},{"key":"10.1016\/j.berh.2018.09.001_bib128","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1001\/jama.2016.5444","article-title":"Polymyalgia rheumatica and giant cell arteritis: a systematic review","volume":"315","author":"Buttgereit","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.berh.2018.09.001_bib129","first-page":"506","article-title":"The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease","volume":"56","author":"Dejaco","year":"2017","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.berh.2018.09.001_bib130","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1136\/annrheumdis-2011-200865","article-title":"Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using ct angiography","volume":"71","author":"Prieto-Gonzalez","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib131","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2217\/ahe.11.50","article-title":"Polymyalgia rheumatica and giant cell arteritis: management of two diseases of the elderly","volume":"7","author":"Dejaco","year":"2011","journal-title":"Aging Health"},{"key":"10.1016\/j.berh.2018.09.001_bib132","first-page":"103","article-title":"Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study","volume":"33","author":"Patil","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib133","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/rheumatology\/kev289","article-title":"The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis?","volume":"55","author":"Diamantopoulos","year":"2016","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.berh.2018.09.001_bib134","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nrrheum.2017.142","article-title":"Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities","volume":"13","author":"Dejaco","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib135","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00108-008-2274-x","article-title":"Polymyalgia rheumatica","volume":"50","author":"Duftner","year":"2009","journal-title":"Der Internist"},{"key":"10.1016\/j.berh.2018.09.001_bib136","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000100","article-title":"Accuracy of musculoskeletal imaging for the diagnosis of polymyalgia rheumatica: systematic review","volume":"1","author":"Mackie","year":"2015","journal-title":"RMD open"},{"key":"10.1016\/j.berh.2018.09.001_bib137","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1136\/annrheumdis-2017-212649","article-title":"Eular recommendations for the use of imaging in large vessel vasculitis in clinical practice","volume":"77","author":"Dejaco","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib138","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.semarthrit.2016.05.009","article-title":"Corticosteroid-related adverse events in patients with giant cell arteritis: a claims-based analysis","volume":"46","author":"Broder","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib139","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","article-title":"2015 recommendations for the management of polymyalgia rheumatica: a european league against rheumatism\/american college of rheumatology collaborative initiative","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib140","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/rheumatology\/keq039a","article-title":"Bsr and bhpr guidelines for the management of giant cell arteritis","volume":"49","author":"Dasgupta","year":"2010","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.berh.2018.09.001_bib141","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/art.22754","article-title":"Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis","volume":"56","author":"Mahr","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib142","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.berh.2018.09.001_bib143","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2018.09.001_bib144","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1136\/ard.2005.046912","article-title":"Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990-2001","volume":"65","author":"Smeeth","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib145","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.23176","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part ii","volume":"58","author":"Lawrence","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib146","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/rheumatology\/kel376","article-title":"Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients","volume":"46","author":"Blockmans","year":"2007","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.berh.2018.09.001_bib147","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/art.21699","article-title":"Repetitive 18f-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients","volume":"55","author":"Blockmans","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib148","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s13075-017-1479-6","article-title":"Incidence of giant cell arteritis in western Norway 1972-2012: a retrospective cohort study","volume":"19","author":"Brekke","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2018.09.001_bib149","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semarthrit.2017.04.001","article-title":"Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015","volume":"47","author":"Crowson","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib150","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/art.30155","article-title":"The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases","volume":"63","author":"Crowson","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib151","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3899\/jrheum.140318","article-title":"Projected worldwide disease burden from giant cell arteritis by 2050","volume":"42","author":"De Smit","year":"2015","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib152","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3109\/03009742.2014.982701","article-title":"The incidence of giant cell arteritis in olmsted county, Minnesota, over a 60-year period 1950-2009","volume":"44","author":"Chandran","year":"2015","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib153","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/acr.23132","article-title":"Epidemiology of polymyalgia rheumatica 2000\u20132014 and examination of incidence and survival trends over 45 years: a population-based study","volume":"69","author":"Raheel","year":"2017","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2018.09.001_bib154","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/acr.22942","article-title":"Incidence, prevalence, and survival of biopsy-proven giant cell arteritis in northern Italy during a 26-year period","volume":"69","author":"Catanoso","year":"2017","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2018.09.001_bib155","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12891-016-1127-3","article-title":"The prevalence of giant cell arteritis and polymyalgia rheumatica in a UK primary care population","volume":"17","author":"Yates","year":"2016","journal-title":"BMC Muscoskel Disord"},{"key":"10.1016\/j.berh.2018.09.001_bib156","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/art.1780330810","article-title":"The american college of rheumatology 1990 criteria for the classification of giant cell arteritis","volume":"33","author":"Hunder","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib157","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/annrheumdis-2011-200329","article-title":"2012 provisional classification criteria for polymyalgia rheumatica: a european league against rheumatism\/american college of rheumatology collaborative initiative","volume":"71","author":"Dasgupta","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib158","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1136\/ard.60.11.1021","article-title":"Presenting features of polymyalgia rheumatica (pmr) and rheumatoid arthritis with pmr-like onset: a prospective study","volume":"60","author":"Caporali","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib159","doi-asserted-by":"crossref","first-page":"43953","DOI":"10.1038\/srep43953","article-title":"Analysis of the common genetic component of large-vessel vasculitides through a meta-immunochip strategy","volume":"7","author":"Carmona","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.berh.2018.09.001_bib160","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/rheumatology\/ket231","article-title":"Genetic component of giant cell arteritis","volume":"53","author":"Carmona","year":"2014","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.berh.2018.09.001_bib161","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ajhg.2016.11.013","article-title":"A\u00a0genome-wide association study identifies risk alleles in plasminogen and p4ha2 associated with giant cell arteritis","volume":"100","author":"Carmona","year":"2017","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.berh.2018.09.001_bib162","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-0033-1334483","article-title":"Plasminogen receptors: the first quarter century","volume":"39","author":"Miles","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.berh.2018.09.001_bib163","doi-asserted-by":"crossref","first-page":"10819","DOI":"10.1074\/jbc.M112.442939","article-title":"Hypoxia-inducible factor 1 (hif-1) promotes extracellular matrix remodeling under hypoxic conditions by inducing p4ha1, p4ha2, and plod 2 expression in fibroblasts","volume":"288","author":"Gilkes","year":"2013","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.berh.2018.09.001_bib164","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1136\/annrheumdis-2013-203641","article-title":"Identification of the ptpn22 functional variant r620w as susceptibility genetic factor for giant cell arteritis","volume":"72","author":"Serrano","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib165","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1002\/art.34647","article-title":"Th1 and th17 lymphocytes expressing cd161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis","volume":"64","author":"Samson","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib166","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/eji.201747092","article-title":"Protein tyrosine phosphatase ptpn22 regulates il-1 beta dependent th17 responses by modulating dectin-1 signaling in mice","volume":"48","author":"Purvis","year":"2018","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.berh.2018.09.001_bib167","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/art.20227","article-title":"Reappraisal of the epidemiology of giant cell arteritis in olmsted county, Minnesota, over a fifty-year period","volume":"51","author":"Salvarani","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib168","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006636","article-title":"Do solar cycles influence giant cell arteritis and rheumatoid arthritis incidence?","volume":"5","author":"Wing","year":"2015","journal-title":"BMJ open"},{"key":"10.1016\/j.berh.2018.09.001_bib169","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0304-3940(99)00308-0","article-title":"Geomagnetic disturbances are associated with reduced nocturnal excretion of a melatonin metabolite in humans","volume":"266","author":"Burch","year":"1999","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.berh.2018.09.001_bib170","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1093\/rheumatology\/38.12.1208","article-title":"The epidemiology of biopsy-positive giant cell arteritis: special reference to cyclic fluctuations","volume":"38","author":"Petursdottir","year":"1999","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2018.09.001_bib171","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/ceo.12069","article-title":"Giant cell arteritis incidence: analysis by season and year in mid-atlantic United States","volume":"41","author":"Kisza","year":"2013","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.berh.2018.09.001_bib172","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1136\/ard.60.4.367","article-title":"Epidemiology of biopsy proven giant cell arteritis in northwestern Spain: trend over an 18 year period","volume":"60","author":"Gonzalez-Gay","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib173","first-page":"112","article-title":"Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of mycoplasma pneumoniae infection","volume":"23","author":"Elling","year":"1996","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib174","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0248-8663(97)83704-6","article-title":"seasonal factor and horton's disease","volume":"19","author":"Ramassamy","year":"1998","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.berh.2018.09.001_bib175","first-page":"S15","article-title":"The incidence of giant cell arteritis in jerusalem over a 25-year period: annual and seasonal fluctuations","volume":"25","author":"Bas-Lando","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib176","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/rheumatology\/33.10.938","article-title":"Giant cell arteritis in jerusalem: a 12-year epidemiological study","volume":"33","author":"Sonnenblick","year":"1994","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib177","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/imj.12293","article-title":"Epidemiology of biopsy-proven giant cell arteritis in south Australia","volume":"44","author":"Dunstan","year":"2014","journal-title":"Intern Med J"},{"key":"10.1016\/j.berh.2018.09.001_bib178","volume":"vol. 3","author":"De Smit","year":"2017"},{"key":"10.1016\/j.berh.2018.09.001_bib179","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/ard.58.10.657","article-title":"There is no association between polymyalgia rheumatica and acute parvovirus b19 infection","volume":"58","author":"Hemauer","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib180","first-page":"361","article-title":"Giant cell arteritis, polymyalgia rheumatica, and viral hypotheses: a multicenter, prospective case-control study. Groupe de recherche sur l'arterite a cellules geantes","volume":"26","author":"Duhaut","year":"1999","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib181","first-page":"309","article-title":"Increased prevalence of antibodies to adenovirus and respiratory syncytial virus in polymyalgia rheumatica","volume":"11","author":"Cimmino","year":"1993","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib182","first-page":"299","article-title":"Antibodies against chlamydia pneumoniae, cytomegalovirus, enteroviruses and respiratory syncytial virus in patients with polymyalgia rheumatica","volume":"15","author":"Uddhammar","year":"1997","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib183","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.38631","article-title":"In search of a candidate pathogen for giant cell arteritis: sequencing-based characterization of the giant cell arteritis microbiome","volume":"66","author":"Bhatt","year":"2014","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.berh.2018.09.001_bib184","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/1529-0131(200007)43:7<1543::AID-ANR19>3.0.CO;2-8","article-title":"Detection of chlamydia pneumoniae in giant cell vasculitis and correlation with the topographic arrangement of tissue-infiltrating dendritic cells","volume":"43","author":"Wagner","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib185","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/1529-0131(199906)42:6<1255::AID-ANR23>3.0.CO;2-P","article-title":"The role of parvovirus b19 in the pathogenesis of giant cell arteritis: a preliminary evaluation","volume":"42","author":"Gabriel","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib186","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1001\/jamaneurol.2015.2101","article-title":"Analysis of varicella-zoster virus in temporal arteries biopsy positive and negative for giant cell arteritis","volume":"72","author":"Nagel","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.berh.2018.09.001_bib187","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/rheumatology\/41.4.445","article-title":"No evidence of parvovirus b19, chlamydia pneumoniae or human herpes virus infection in temporal artery biopsies in patients with giant cell arteritis","volume":"41","author":"Helweg-Larsen","year":"2002","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2018.09.001_bib188","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1128\/JCM.02438-08","article-title":"No correlation between giant cell arteritis and chlamydia pneumoniae infection: investigation of 189 patients by standard and improved PCR methods","volume":"47","author":"Njau","year":"2009","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.berh.2018.09.001_bib189","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jcv.2004.05.003","article-title":"No detection of parvovirus b19 or herpesvirus DNA in giant cell arteritis","volume":"31","author":"Rodriguez-Pla","year":"2004","journal-title":"J\u00a0Clin Virol : Off Publ Pan Am Soc Clin Virol"},{"key":"10.1016\/j.berh.2018.09.001_bib190","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1002\/art.40236","article-title":"Herpes zoster as a risk factor for incident giant cell arteritis","volume":"69","author":"England","year":"2017","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.berh.2018.09.001_bib191","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3109\/03009742.2013.793777","article-title":"Occupational and socio-economic risk factors for giant cell arteritis: a nationwide study based on hospitalizations in Sweden","volume":"42","author":"Zoller","year":"2013","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib192","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1080\/03009742.2016.1266030","article-title":"Risk of ocular manifestations in patients with giant cell arteritis: a nationwide study in Sweden","volume":"46","author":"Ji","year":"2017","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib193","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/1529-0131(199811)41:11<1960::AID-ART10>3.0.CO;2-X","article-title":"Giant cell arteritis and cardiovascular risk factors: a multicenter, prospective case-control study","volume":"41","author":"Duhaut","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib194","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/01.md.0000145369.25558.b5","article-title":"Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis","volume":"83","author":"Gonzalez-Gay","year":"2004","journal-title":"Medicine"},{"key":"10.1016\/j.berh.2018.09.001_bib195","first-page":"753","article-title":"Giant cell arteritis and vascular disease-risk factors and outcomes: a cohort study using UK clinical practice research datalink","volume":"56","author":"Li","year":"2017","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.berh.2018.09.001_bib196","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/rheumatology\/38.2.118","article-title":"Giant cell arteritis and polymyalgia rheumatica: are pregnancies a protective factor? A prospective, multicentre case-control study","volume":"38","author":"Duhaut","year":"1999","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.berh.2018.09.001_bib197","first-page":"232","article-title":"Lower body mass index is associated with a higher risk of giant cell arteritis: a systematic review and meta-analysis","volume":"3","author":"Ungprasert","year":"2015","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.berh.2018.09.001_bib198","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3109\/14397595.2015.1081722","article-title":"Patients with giant cell arteritis have a lower prevalence of diabetes mellitus: a systematic review and meta-analysis","volume":"26","author":"Ungprasert","year":"2016","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib199","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3899\/jrheum.151024","article-title":"Which patients with giant cell arteritis will develop cardiovascular or cerebrovascular disease? A clinical practice research datalink study","volume":"43","author":"Robson","year":"2016","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib200","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/rheumatology\/kev262","article-title":"Increased risk of cardiovascular disease in giant cell arteritis: a general population-based study","volume":"55","author":"Amiri","year":"2016","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.berh.2018.09.001_bib201","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/acr.21712","article-title":"Association between polymyalgia rheumatica and vascular disease: a systematic review","volume":"64","author":"Hancock","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2018.09.001_bib202","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/1529-0131(199808)41:8<1497::AID-ART22>3.0.CO;2-Z","article-title":"Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment","volume":"41","author":"Gonzalez-Gay","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib203","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/art.21075","article-title":"Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis","volume":"53","author":"Salvarani","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib204","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1055\/s-2001-18387","article-title":"bilateral amaurosis in 11 patients with giant cell arteritis confirmed by arterial biopsy","volume":"218","author":"Wenkel","year":"2001","journal-title":"Klin Monatsblatter fur Augenheilkunde"},{"key":"10.1016\/j.berh.2018.09.001_bib205","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.semarthrit.2015.06.009","article-title":"Prevalence of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica","volume":"45","author":"Narvaez","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib206","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(08)61077-6","article-title":"Polymyalgia rheumatica and giant-cell arteritis","volume":"372","author":"Salvarani","year":"2008","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.berh.2018.09.001_bib207","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/annrheumdis-2013-204113","article-title":"The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK","volume":"74","author":"Robson","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib208","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/01.md.0000145366.40805.f8","article-title":"Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study","volume":"83","author":"Gonzalez-Gay","year":"2004","journal-title":"Medicine"},{"key":"10.1016\/j.berh.2018.09.001_bib209","first-page":"324","article-title":"Giant cell arteritis and cardiovascular disease in older adults","volume":"91","author":"Ray","year":"2005","journal-title":"Heart (Br Cardiac Soc)"},{"key":"10.1016\/j.berh.2018.09.001_bib210","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1136\/annrheumdis-2012-202408","article-title":"Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis","volume":"72","author":"Kermani","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib211","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3899\/jrheum.131254","article-title":"Polymyalgia rheumatica (pmr) special interest group at omeract 11: outcomes of importance for patients with pmr","volume":"41","author":"Mackie","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib212","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.pec.2014.12.013","article-title":"I\u00a0suddenly felt I'd aged\": a qualitative study of patient experiences of polymyalgia rheumatica (pmr)","volume":"98","author":"Twohig","year":"2015","journal-title":"Patient Educ Counsel"},{"key":"10.1016\/j.berh.2018.09.001_bib213","first-page":"171","article-title":"Prognostic factors and long-term evolution in a cohort of 133 patients with giant cell arteritis","volume":"19","author":"Hachulla","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib214","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/art.20901","article-title":"Acute-phase reactants and the risk of relapse\/recurrence in polymyalgia rheumatica: a prospective followup study","volume":"53","author":"Salvarani","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib215","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/MD.0000000000000033","article-title":"Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients","volume":"93","author":"Alba","year":"2014","journal-title":"Medicine"},{"key":"10.1016\/j.berh.2018.09.001_bib216","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1136\/annrheumdis-2015-207578","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib217","first-page":"S30","article-title":"Giant cell arteritis: intensity of the initial systemic inflammatory response and the course of the disease","volume":"26","author":"Nesher","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib218","doi-asserted-by":"crossref","first-page":"e3524","DOI":"10.1097\/MD.0000000000003524","article-title":"Flares in biopsy-proven giant cell arteritis in northern Italy: characteristics and predictors in a long-term follow-up study","volume":"95","author":"Restuccia","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.berh.2018.09.001_bib219","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.semarthrit.2016.10.001","article-title":"Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis","volume":"46","author":"Wilson","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib220","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3899\/jrheum.160249","article-title":"Rate of comorbidities in giant cell arteritis: a population-based study","volume":"44","author":"Mohammad","year":"2017","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib221","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000521","article-title":"Association between glucocorticoid therapy and incidence of diabetes mellitus in polymyalgia rheumatica and giant cell arteritis: a systematic review and meta-analysis","volume":"4","author":"Lai","year":"2018","journal-title":"RMD open"},{"key":"10.1016\/j.berh.2018.09.001_bib222","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12916-017-0987-1","article-title":"Risk of fracture among patients with polymyalgia rheumatica and giant cell arteritis: a population-based study","volume":"16","author":"Paskins","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.berh.2018.09.001_bib223","doi-asserted-by":"crossref","first-page":"R50","DOI":"10.1186\/ar2664","article-title":"Increased risk of peripheral arterial disease in polymyalgia rheumatica: a population-based cohort study","volume":"11","author":"Warrington","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2018.09.001_bib224","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/1756-185X.12631","article-title":"Peripheral arterial disease in patients with giant cell arteritis: a meta-analysis","volume":"19","author":"Ungprasert","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib225","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/art.39596","article-title":"Incidence of severe infections and infection-related mortality during the course of giant cell arteritis: a multicenter, prospective, double-cohort study","volume":"68","author":"Schmidt","year":"2016","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.berh.2018.09.001_bib226","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1136\/ard.2008.100008","article-title":"Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis","volume":"68","author":"Hoes","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib227","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.semarthrit.2014.06.004","article-title":"Risk of malignancy in patients with giant cell arteritis and polymyalgia rheumatica: a systematic review and meta-analysis","volume":"44","author":"Ungprasert","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib228","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/ard.2010.133850","article-title":"Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a delphi-based expert consensus","volume":"70","author":"Dejaco","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib229","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1136\/ard.2003.011379","article-title":"A\u00a0disease activity score for polymyalgia rheumatica","volume":"63","author":"Leeb","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.09.001_bib230","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/art.23338","article-title":"Performance of the polymyalgia rheumatica activity score for diagnosing disease flares","volume":"59","author":"Binard","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib231","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/art.22771","article-title":"The polymyalgia rheumatica activity score in daily use: proposal for a definition of remission","volume":"57","author":"Leeb","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib232","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3899\/jrheum.141179","article-title":"Development of a provisional core domain set for polymyalgia rheumatica: report from the omeract 12 polymyalgia rheumatica working group","volume":"43","author":"Helliwell","year":"2016","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib233","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/art.10262","article-title":"A\u00a0multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis","volume":"46","author":"Hoffman","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.09.001_bib234","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","article-title":"Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial","volume":"146","author":"Hoffman","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2018.09.001_bib235","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.3899\/jrheum.161269","article-title":"Assessment of disease activity in large-vessel vasculitis: results of an international delphi exercise","volume":"44","author":"Aydin","year":"2017","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib236","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.3899\/jrheum.161467","article-title":"Development of a core set of outcome measures for large-vessel vasculitis: report from omeract 2016","volume":"44","author":"Sreih","year":"2017","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib237","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3899\/jrheum.151063","article-title":"The birmingham vasculitis activity score as a measure of disease activity in patients with giant cell arteritis","volume":"43","author":"Kermani","year":"2016","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2018.09.001_bib238","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/rheumatology\/kex477","article-title":"Assessing polymyalgia rheumatica activity when c-reactive protein is unavailable or uninterpretable","volume":"57","author":"Devauchelle-Pensec","year":"2018","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.berh.2018.09.001_bib239","article-title":"Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmicantibody-associated glomerulonephritis in a 20-year population-based cohort","author":"Berti","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.berh.2018.09.001_bib240","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.rmed.2018.07.017","article-title":"Severe\/uncontrolled asthma and overall survival in atopic patients with eosinophilic granulomatosis with polyangiitis","volume":"142","author":"Berti","year":"2018","journal-title":"Respir Med"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694218300500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694218300500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:17:55Z","timestamp":1761499075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694218300500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":240,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S1521694218300500"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2018.09.001","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on the epidemiology, risk factors, and outcomes of systemic vasculitides","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2018.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}